Nanomedicine News

RSS

MagForce Holds Meeting with FDA Center for Devices and Radiological Health for NanoTherm Therapy Pre-Submission

MagForce AG (Frankfurt, Entry Standard), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. are pleased to report that an in-person meeting was held with the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health to discuss FDA's response to MagForce's NanoTherm® Therapy Pre-Submission of late December, 2013.

6 May 2014

Researchers Receive Funding to Explore Ways to Improve Heart Disease Treatment Using Nanoparticles

A study to investigate how nanoparticles could be used to improve the diagnosis and treatment of cardiovascular disease has received £3 million funding.

2 May 2014

Liquidia to Report Study Results on Next-Generation Multivalent PRINT Nanoparticle Pneumococcal Vaccine

Liquidia Technologies today announced that it will present findings from preclinical proof-of-concept studies conducted with its next generation, multivalent pneumococcal vaccine that is based on the company’s novel PRINT® (Particle Replication In Non-Wetting Templates) technology.

From Liquidia Technologies, Inc. 2 May 2014

Experimental Protein Nanoparticle Vaccine Shows Potential to Respond Rapidly to Emerging Viruses

The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus (MERS-CoV) blocked infection in laboratory studies.

From Novavax Inc. 2 May 2014

Biodegradable Nanoparticles Can Carry DNA to Brain Cancer Cells

Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable "nanoparticles" able to carry DNA to brain cancer cells in mice.

30 Apr 2014

Senesco to Present on Cancer-Targeted Gene Therapy and Cell Therapy

Senesco Technologies, Inc. (“Senesco” or the “Company”), announced today that an oral presentation will be delivered on its potential approach to treating hepatocellular carcinoma at the 17th Annual Meeting of the American Society of Gene & Cell Therapy during the session entitled “Cancer-Targeted Gene & Cell Therapy II”.

29 Apr 2014

Novavax Unveiled Evaluation Data of RSV-F Protein Nanoparticle Vaccine in Clinical Trial

Novavax, Inc. today announced positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in women of childbearing age. The randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety of multiple formulations of Novavax' RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate.

From Novavax Inc. 29 Apr 2014

Tekmira Presents New Clinical data for Patisiran for Treating ATTR

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented new clinical data for patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology. The program represents the most clinically advanced application of Tekmira's proprietary LNP delivery technology.

29 Apr 2014

Forecast Report on Global Nanomedicine Market

Research and Markets have announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering.

From Research and Markets 28 Apr 2014

pSivida Selected for the Ophthalmic Companies Showcase at the OIS at Boston, MA

pSivida Corp., a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA.

From EyePoint Pharmaceuticals, Inc. 26 Apr 2014

Nanomedicine News

MagForce Holds Meeting with FDA Center for Devices and Radiological Health for NanoTherm Therapy Pre-Submission

Researchers Receive Funding to Explore Ways to Improve Heart Disease Treatment Using Nanoparticles

Liquidia to Report Study Results on Next-Generation Multivalent PRINT Nanoparticle Pneumococcal Vaccine

Experimental Protein Nanoparticle Vaccine Shows Potential to Respond Rapidly to Emerging Viruses

Biodegradable Nanoparticles Can Carry DNA to Brain Cancer Cells

Senesco to Present on Cancer-Targeted Gene Therapy and Cell Therapy

Novavax Unveiled Evaluation Data of RSV-F Protein Nanoparticle Vaccine in Clinical Trial

Tekmira Presents New Clinical data for Patisiran for Treating ATTR

Forecast Report on Global Nanomedicine Market

pSivida Selected for the Ophthalmic Companies Showcase at the OIS at Boston, MA

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials